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Introduction
Inflammation and inflammatory mediators may affect glu-
cose and lipid metabolism through a number of pathways.
However, effects and mechanisms seem to vary dramati-
cally in different individuals and settings. In obese adults
with metabolic syndrome and impaired glucose-tolerance,
inflammatory mediators from fat tissue including tumour
necrosis factor-alpha (TNF-a) further reduce glucose tol-
erance. In such patients, treatment with TNF-a-blocking
agents has been shown to ameliorate glucose tolerance.
However, in non-obese healthy adults, vigorous exercise
may induce an inflammatory response including release of
TNF-a. Glucose tolerance increases during and after the
exercise, and TNF-a blocking agents may inhibit this ben-
eficial effect. Furthermore, the positive effects of exercise
on cholesterol and triglyceride levels have also been
diminished by TNF-a blocking agents.
In children with juvenile idiopathic arthritis (JIA) treat-
ment with TNF-a blocking agents is increasingly com-
mon as the treatment is efficient and well tolerated. The
possible harmful effects of this treatment on glucose and
lipid metabolism, however, give rise to concern.
Objectives
The aim of the study was to investigate the glucose and
lipid metabolism in children with JIA treated with TNF-
a blocking agents.
Methods
Fifty-two children with JIA were included in the study. All
were treated with immunosuppressive agents: 30 were
treated with methotrexate (MTX) in monotherapy, 13
were treated with MTX and a TNF-a blocking agent and
9 were treated with a TNF-a blocking agent in monother-
apy. None were treated with oral glucocorticoids. All treat-
ments had been given at least 3 months at the time of
blood sampling.
All participants had a fasting blood sample drawn and
subsequently the following parameters were assessed:
HgbA1C (an indicator of the average blood glucose in
the 8 weeks prior to testing), fasting blood glucose, total
cholesterol, high density lipoprotein (HDL), low density
lipoprotein (LDL) and triglyceride.
Results
Table 1
The data were tested and found to be normally dis-
tributed. Thus, unpaired t-test was used to compare
mean-values.
Mean HgbA1C was significantly lower children treated
with a TNF-a blocking agent compared to children trea-
ted with MTX as monotherapy (p = 0.01). The differ-
ence was significant in both children treated with TNF-
blocker as monotherapy (p = 0.05) or in combination
with MTX (p = 0.03). No other significant differences
were detected.
Conclusion
Children with JIA treated with a TNF-a blocking agent
have significantly lower HgbA1C. The reduction, however,
is small and barely of clinical significance. No effects could
be detected on fasting blood glucose or cholesterol levels.
The results are reassuring with regard to the concerns for
harmful long term side effects of this treatment.
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Table 1
Treatment HgbA1C/percent Fasting blood glucose/mM Total cholesterol/mM HDL/mM LDL/mM Triglyceride/mM
MTX 5.3 (0.3) 5.0 (0.5) 4.0 (0.7) 1.5 (0.4) 2.1 (0.5) 0.7 (0.3)
MTX and TNF-a blocker 5.1 (0.3) 5.0 (0.5) 4.1 (1.2) 1.4 (0.2) 2.3 (0.9) 1,1 (0.8)
TNF-a blocker 5.1 (0.2) 4.9 (0.5) 3.9 (0.7) 1.4 (0.3) 2.3 (0.5) 0.6 (0.2)
All values as mean (SD).
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